المؤلفون: Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O'Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph D., Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

المصدر: Cancer Research

مصطلحات موضوعية: Ipilimumab, NSCLC, Nivolumab, Platinum-doublet chemotherapy

وصف الملف: application/pdf

العلاقة: https://eprints.qut.edu.au/133393/1/133393.pdfTest; Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O'Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph D., Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, & Paz-Ares, Luis (2018) Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. Cancer Research, 17(13_Supplement), CT077.; https://eprints.qut.edu.au/133393Test/

الإتاحة: https://doi.org/10.1158/1538-7445.AM2018-CT077Test
https://eprints.qut.edu.au/133393Test/

المؤلفون: Ramalingam, Suresh, Hellmann, Matthew, Awad, Mark, Borghaei, Hossein, Gainor, Justin, Brahmer, Julie, Spigel, David, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, other, and

المصدر: Cancer Research

مصطلحات موضوعية: Ipilimumab, NSCLC, Nivolumab, Tumour mutational burden

وصف الملف: application/pdf

العلاقة: https://eprints.qut.edu.au/133391/1/133391.pdfTest; Ramalingam, Suresh, Hellmann, Matthew, Awad, Mark, Borghaei, Hossein, Gainor, Justin, Brahmer, Julie, Spigel, David, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, & other, and (2018) Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Research, 78(13S), CT078-CT078.; https://eprints.qut.edu.au/133391Test/; Faculty of Health; Institute of Health and Biomedical Innovation; School of Biomedical Sciences

الإتاحة: https://doi.org/10.1158/1538-7445.AM2018-CT078Test
https://eprints.qut.edu.au/133391Test/